In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a four-year global research collaboration agreement with Verve Therapeutics. Under the agreement, which is worth up to US$466 M, the companies will discover and develop an in vivo gene editing programme for a single undisclosed liver disease. The deal aligns with Vertex’s strategic move to explore new modalities such as gene therapies for the treatment of patients with liver diseases and offers Verve the opportunity to conduct research and expand its pipeline across a new therapeutic indication.